Bank of New York Mellon
SVNT

Bank of New York Mellon’s SAVIENT PHARMACEUTICALS INC SVNT Stock Holding History

Bank of New York Mellon’s Portfolio SVNT Stock Details SVNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-120,548
Closed -$68K – 4240
2013
Q2 		$68K Buy
+120,548
New +$84K ﹤0.01% 3997

Other funds holding SVNT

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon's SVNT Position: Q3 2013 in Review

Bank of New York Mellon sold out of SAVIENT PHARMACEUTICALS INC (SVNT) in Q3 2013, closing a stake of 120,548 shares — an estimated $68K sold.

Bank of New York Mellon first reported a position in SVNT in Q2 2013 and held it in 1 quarter. The position peaked at $68K in Q2 2013. 41 funds tracked by Wall St. Rank hold SVNT as of Q3 2013.

  • Bank of New York Mellon reported no remaining SAVIENT PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • Bank of New York Mellon sold 120,548 SAVIENT PHARMACEUTICALS INC shares in Q3 2013, an estimated $68K.
  • Bank of New York Mellon first reported a position in SAVIENT PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • Bank of New York Mellon's SAVIENT PHARMACEUTICALS INC position peaked at $68K in Q2 2013.
  • 41 funds tracked by Wall St. Rank held SAVIENT PHARMACEUTICALS INC as of Q3 2013.

Based on Bank of New York Mellon's 13F filing for Q3 2013, filed 13 Nov 2013.